de Klerk JM - Search Results

1

Integrated visualization of functional and anatomic brain data: a validation study.

Stokking R, van Isselt JW, van Rijk PP, de Klerk JM, Huiskes AW, Mertens IJ, Buskens E, Viergever MA. Stokking R, et al. Among authors: de klerk jm. J Nucl Med. 1999 Feb;40(2):311-6. J Nucl Med. 1999. PMID: 10025840 Free article.

2

Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.

de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. de Klerk JM, et al. J Nucl Med. 1992 May;33(5):646-51. J Nucl Med. 1992. PMID: 1373767 Free article.

3

Technetium-99m-MAG3 versus iodine-123-OIH: renal clearance and distribution volume as measured by a constant infusion technique.

Prenen JA, de Klerk JM, van het Schip AD, van Rijk PP. Prenen JA, et al. Among authors: de klerk jm. J Nucl Med. 1991 Nov;32(11):2057-60. J Nucl Med. 1991. PMID: 1834812 Free article.

4

Can technetium 99m bisdiethylphosphinoethanebis-t butylisocyanide (99mTc-DEPIC) be used for routine radionuclide ventriculography?

de Klerk JM, van Rijk PP, van Dongen AJ, Deenstra M, Bànki JH, van het Schip AD. de Klerk JM, et al. Eur J Nucl Med. 1991;18(5):317-20. doi: 10.1007/BF02285458. Eur J Nucl Med. 1991. PMID: 1936039

5

Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.

de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP. de Klerk JM, et al. Eur J Nucl Med. 1994 Oct;21(10):1114-20. doi: 10.1007/BF00181067. Eur J Nucl Med. 1994. PMID: 7530199 Clinical Trial.

6

Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome.

de Bruin TW, Croon CD, de Klerk JM, van Isselt JW. de Bruin TW, et al. Among authors: de klerk jm. J Intern Med. 1994 Nov;236(5):507-13. doi: 10.1111/j.1365-2796.1994.tb00837.x. J Intern Med. 1994. PMID: 7964426

7

Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.

de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, Blijham GH, van Rijk PP. de Klerk JM, et al. J Nucl Med. 1994 Sep;35(9):1423-8. J Nucl Med. 1994. PMID: 8071686 Free article.

8

Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.

de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP. de Klerk JM, et al. J Nucl Med. 1996 Jan;37(1):38-41. J Nucl Med. 1996. PMID: 8543998 Free article.

9

Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.

de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP. de Klerk JM, et al. J Nucl Med. 1996 Feb;37(2):244-9. J Nucl Med. 1996. PMID: 8667053 Free article. Clinical Trial.

10

Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.

de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP. de Klerk JM, et al. J Nucl Med. 1996 Mar;37(3):465-7. J Nucl Med. 1996. PMID: 8772646 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters